Study #2022-0429
A phase 2 trial of EO2040, a microbiaL-derived peptide therapeutic vaccine, in combination with nivolumab, for treatment of patients with circulating tumor DNA-defined minimal residual disease of colorectal cancer stage II, III, or IV after completion of
MD Anderson Study Status
Not Accepting
Treatment Agent
EO2040
Description
The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Colorectal Cancer
Study phase:
Phase II
Physician name:
Arvind Nageshwara Vijaya Dasari
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-581-8877
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.